immatics biotechnologies
Clinical-stage biotechnology company focused on discovery, engineering and clinical development of T cell receptor (TCR)-based immunotherapies. Core activities include mass-spectrometry‑guided target discovery, TCR discovery and engineering, development of autologous and allogeneic cell therapies and TCR-based bispecific biologics, GMP clinical manufacturing and clinical development across multiple phases (including an ongoing randomized Phase 3 trial). The company maintains strategic research collaborations with external partners spanning mRNA modalities, gene editing and clinical research institutions.
Industries
Nr. of Employees
large (251-1000)
immatics biotechnologies
Patents
Peptides and combination of peptides for use in immunotherapy against cancers
US-12466878-B2
View DetailsPeptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
US-12351616-B2
View DetailsPeptides displayed by HLA for use in immunotherapy against different types of cancers
US-12318407-B2
View Details
Peptides and combination of peptides for use in immunotherapy against cancers
US-12466878-B2
View DetailsPeptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
US-12351616-B2
View DetailsPeptides displayed by HLA for use in immunotherapy against different types of cancers
US-12318407-B2
View DetailsProducts
PRAME-directed autologous TCR T-cell therapy (lead candidate IMA203)
Autologous engineered TCR T-cell therapy targeting PRAME for PRAME-expressing solid tumors. Program has progressed through early-phase studies and is being evaluated in a randomized Phase 3 trial (SUPRAME) assessing efficacy and safety versus investigator’s choice in previously treated advanced cutaneous melanoma.
PRAME-directed CD8-focused TCR T-cell therapy (IMA203CD8)
CD8-focused TCR T-cell product candidate directed against PRAME evaluated in early-phase clinical trials for PRAME-positive solid tumors.
PRAME-targeting TCR bispecific (IMA402)
Off-the-shelf TCR-based bispecific molecule targeting PRAME being developed as monotherapy and in combination with checkpoint inhibitors and other modalities; currently in early clinical evaluation.
MAGEA4/8-targeting TCR bispecific (IMA401)
TCR-based bispecific molecule targeting MAGEA4/8 developed for multiple solid tumor indications and evaluated in first-in-human clinical studies.
COL6A3-targeted TCR T-cell therapy (IMA204)
TCR T-cell therapy candidate directed at a tumor stroma antigen (COL6A3 exon 6) designed to engage both CD8+ and CD4+ responses via a CD8-independent TCR.
Allogeneic gamma-delta T cell platform
Development program for an off-the-shelf adoptive cell therapy using gene-engineered gamma-delta T cells from healthy donors to enable multi-dose production from a single donor leukapheresis.
PRAME-directed autologous TCR T-cell therapy (lead candidate IMA203)
Autologous engineered TCR T-cell therapy targeting PRAME for PRAME-expressing solid tumors. Program has progressed through early-phase studies and is being evaluated in a randomized Phase 3 trial (SUPRAME) assessing efficacy and safety versus investigator’s choice in previously treated advanced cutaneous melanoma.
PRAME-directed CD8-focused TCR T-cell therapy (IMA203CD8)
CD8-focused TCR T-cell product candidate directed against PRAME evaluated in early-phase clinical trials for PRAME-positive solid tumors.
PRAME-targeting TCR bispecific (IMA402)
Off-the-shelf TCR-based bispecific molecule targeting PRAME being developed as monotherapy and in combination with checkpoint inhibitors and other modalities; currently in early clinical evaluation.
MAGEA4/8-targeting TCR bispecific (IMA401)
TCR-based bispecific molecule targeting MAGEA4/8 developed for multiple solid tumor indications and evaluated in first-in-human clinical studies.
COL6A3-targeted TCR T-cell therapy (IMA204)
TCR T-cell therapy candidate directed at a tumor stroma antigen (COL6A3 exon 6) designed to engage both CD8+ and CD4+ responses via a CD8-independent TCR.
Allogeneic gamma-delta T cell platform
Development program for an off-the-shelf adoptive cell therapy using gene-engineered gamma-delta T cells from healthy donors to enable multi-dose production from a single donor leukapheresis.
Expertise Areas
- Immunopeptidomics and peptide–HLA target discovery
- TCR discovery, engineering and validation
- Development of TCR-based bispecific biologics
- Autologous and allogeneic cell therapy development
Key Technologies
- High-sensitivity mass spectrometry for HLA ligand discovery
- Immunopeptidomics
- T cell receptor discovery and engineering
- TCR-based bispecific engager formats
News & Updates
Strategic multi-platform R&D collaboration with an mRNA developer announced September 2023 covering bispecifics, cell therapy and cancer vaccines.
Research collaboration and licensing agreement to combine gamma-delta adoptive cell therapies and gene editing announced June 2022.
Strategic partnership with a clinical cancer center to establish US operations and develop T-cell and TCR-based adoptive cellular therapies (announced August 2015).
Presentation of clinical activity and response dynamics for the PRAME-directed cell therapy candidate at ASCO 2026.
Publication reporting a TCR-based bispecific targeting MAGE-A4/A8 and first-in-human trial data (Nature Medicine, 2026).
Manuscript describing a TCR bispecific scaffold optimized for targeting peptide–HLA antigens (mAbs, 2026).
Strategic multi-platform R&D collaboration with an mRNA developer announced September 2023 covering bispecifics, cell therapy and cancer vaccines.
Research collaboration and licensing agreement to combine gamma-delta adoptive cell therapies and gene editing announced June 2022.
Strategic partnership with a clinical cancer center to establish US operations and develop T-cell and TCR-based adoptive cellular therapies (announced August 2015).
Presentation of clinical activity and response dynamics for the PRAME-directed cell therapy candidate at ASCO 2026.
Publication reporting a TCR-based bispecific targeting MAGE-A4/A8 and first-in-human trial data (Nature Medicine, 2026).
Manuscript describing a TCR bispecific scaffold optimized for targeting peptide–HLA antigens (mAbs, 2026).